key: cord-0256384-g9e5qr6m
authors: Yang, Xinyi; Zhu, Yuqi; Zhao, Xiaying; Liu, Jun; Xun, Jiangna; Yuan, Songhua; Chen, Jun; Pan, Hanyu; Yang, Jinlong; Wang, Jing; Liang, Zhimin; Shen, Xiaoting; Liang, Yue; Lin, Qinru; Liang, Huitong; Li, Min; Lu, Hongzhou; Zhu, Huanzhang
title: ASGR1 is a candidate receptor for SARS-CoV-2 that promotes infection of liver cells
date: 2022-01-18
journal: bioRxiv
DOI: 10.1101/2022.01.15.476426
sha: 40f0340e048d7da893ec11833999f8d80101654e
doc_id: 256384
cord_uid: g9e5qr6m

Backgroud & Aims Currently, the COVID-19 pandemic, caused by SARS-CoV-2 infection, represents a serious public health problem worldwide. Although it has been shown that ACE2 serves as the main receptor for SARS-CoV-2 entry into host cells, studies have shown that ACE2 is expressed at extremely low levels in various tissues, especially in some organs where virus particles have been found, such as the heart and liver. Therefore, these organs potentially express additional SARS-CoV-2 receptors that have not yet been discovered. Methods & Results Here, by a genome-wide CRISPR-Cas9 activation library screening, we found that ASGR1 promoted SARS-CoV-2 infection of 293T cells. In Huh-7 and HepG2 cell lines, simultaneous knock out of ACE2 and ASGR1 prevented SARS-CoV-2 pseudovirus infection. In the immortalized THLE-2 hepatocyte cell line and primary liver parenchymal cells, both of which hardly express ACE2, SARS-CoV-2 could successfully establish an infection. After treatment with ASGR1 antibody, the infection rate significantly reduced. This suggests that SARS-CoV-2 infects liver cells mainly through an ASGR1-dependent mechanism. Finally, we also found that the soluble ASGR1 could not only prevent the SARS-CoV-2 pseudovirus, which binds to the ASGR1 receptors, from infecting host liver cells, but also had a protective effect on those expressing ACE2, indicating that administration of soluble ASGR1 protein may represent a new treatment approach. Conclusions Colletively, these findings indicate that ASGR1 is a candidate receptor for SARS-CoV-2 that promotes infection of liver cells. Lay Summary We show that ASGR1 is a candidate receptor for SARS-CoV-2 to infect liver cells.

This work was supported by the National Natural Science Foundation of China 27 (82041001, 31771484, 81761128020) . The funders had no roles in experimental 28 design, data collection and analysis, interpretation of the data, or writing of this paper. 

The COVID-19 outbreak, an acute infectious disease caused by severe acute 77 respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic, 78 as well as serious public health problems since December 2019 [1] . SARS-CoV-2 is a 79 betacoronavirus with a positive-strand RNA genome [2, 3] . It is currently the third 80 coronavirus causing global public health problems; the first two are severe acute 81 respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) 82 coronaviruses [4, 5] . In previous studies, researchers have found that SARS-CoV-2 83 mainly infects human respiratory cells, especially lung cells [6] . In addition, 84 SARS-CoV-2 could be detected in multiple organs, including the heart, liver, kidney, 85 and intestine [7] [8] [9] [10] [11] . 86 Similar to SARS-CoV, researchers found that SARS-CoV-2 enters lung cells 87 mainly through interactions of the viral S protein and the cellular ACE2 receptor 88 [12, 13] . Although ACE2 and S proteins display high affinity binding, and cell lines 89 overexpressing ACE2 can be infected by , experimental results 90 obtained by single-cell sequencing showed that many tissues and cells can be 91 infected by SARS-CoV-2, even if the expression level of ACE2 is low. This suggests 92 that there may be cellular receptors for SARS-CoV-2 other than ACE2 [14] [15] [16] . 93 The liver is an important organ in the human body.In the process of clinical 94 treatment, researchers have found that some patients with SARS-CoV-2 have visible 95 pathological damage and inflammation in the liver [17, 18] . Meanwhile, SARS-CoV-2 96 was present in patient-derived liver samples upon pathological examination of tissues 97 isolated from corpses [8] . In in vitro experiments, multiple liver-derived cell lines could 98 be infected with SARS-CoV-2, but single-cell sequencing results showed that the 99 expression level of ACE2 in liver cells is very low [19] . Therefore, we speculated that 100 liver cells may express a non-ACE2 SARS-CoV-2 receptor. in a 37 °C incubator containing 5% CO2. THLE-2 and primary hepatocytes cells were 134 cultured BEGM (Lonza, Construction and production of pseudoviruses 150 The spike of SARS-CoV-2 and that of all variant plasmids were synthesized by 151 the GeneScript Company. All S proteins were optimized with 18 amino acids removed 152 and an HA tag attached. The core plasmid, pLenti.GFP.NLuc-Puromycin, that 153 expresses GFP, luciferase and puromycin at the same time was maintained in our 154 laboratory.

For production of pseudoviruses, HEK293T/17 cells were seeded into 10cm 156 dishes one day before transfection. When the cells reached 80% confluence, plasmid 157 and PEI were added into the Opti-MDM (Gibco), mixed evenly, and left standing for 158 20min. pLenti.GFP.NLuc, psPAX2 and the S protein vector were co-transfected into 159 HEK293T/17 cells to produce the pseudoviruses. After incubation at 37°C and 5% 160 CO2 for 24h, the culture medium was changed with DMEM with 2% FBS and 1% P/S.

The supernatants containing SARS-CoV-2 pseudotyped viruses were harvested at 162 48h and 72h after transfection and filtered by 0.45μm pore size. The filtrates were 163 centrifuged at 25000rpm and 4°C for 2h. The supernatants were discarded, and the 164 pseudovirus stocks were dissolved in DMEM for storage at -80°C [25] [26] [27] . 

To identify viral entry factors for SARS-CoV-2, we established SAM library 236 screening [30] in HeLa cells, which has been proven by us and other researchers that 237 it cannot be infected with the SARS-CoV-2 pseudovirus [12] (Fig. 1F-1G ). This SAM 238 library contains over 70920 gRNAs for 23430 human genes [30] . We prepared MPH 239 lentivirus to infect HeLa cells with a multiplicity of infection (MOI) of 10, after which the 240 cells were subjected to hygromycin (200 µg/ml) selection for 14 days ( Fig. 2A) . We 241 extracted the genome of the selected cell line and identified it by PCR using primers 242 specifically targeting the MPH plasmid region. We found that infected and 243 drug-screened cell lines had integrated the p65 gene sequence in MPH management 244 (Fig. 2B) . We also prepared a SAM library lentivirus to infect HeLa-MPH cells with an 245 MOI of 0.2, with the aim of single cells being infected by only one virus particle. Then, 246 the cells were selected with blasticidin, and Cas9 expression was analyzed by 247 western blotting with anti-Cas9 antibody ( Fig. 2A and 2C ).

After preparing the cell library, we prepared a pseudovirus containing a 249 GFP-luciferase-puromycin construct packaged with S protein to infect the cells from 250 our library at an MOI of 10. Next, puromycin was added to select cells that had been 251 successfully infected ( Fig. 2A) . After the screening process, we found that most of the 252 cells had died, and the surviving cells grew into single clones. Therefore, we 253 expanded these surviving monoclonal cell populations, extracted the cellular genome, 254 and sequenced the sgRNA sequences present in these monoclonal cells by Sanger 255 sequencing (Fig. 2D) . Through statistical analysis, we obtained a total of 13 sgRNAs 256 targeting different genes, including ACE2. In addition to ACE2, we found the genes 257 encoding CD134, KREMEN1, ASGR1, and CXCR24 membrane proteins (Fig. 2D ).

Considering that SARS-CoV-2 enters cells mainly through interaction of the S protein 259 and membrane proteins, we focused on the above-mentioned membrane proteins for 260 subsequent experiments. To test whether these candidate genes were relevant to SARS-CoV-2 entry into 264 the cells, we infected 293T cells with lentiviruses carrying different candidate genes, 265 followed by clonal selection with puromycin (2 µg/ml) for 14 days. Next, we used S 266 protein-packaged pseudovirus containing GFP and luciferase to infect the 267 aforementioned cell lines. Using fluorescence microscopy, we found that in addition to 268 293T-ACE2 cells, 293T-ASGR1 cells were susceptible to infection with SARS-CoV-2 269 pseudovirus (Fig. 2E) . We further confirmed these results through flow cytometry and 270 luciferase reporter gene analysis (Fig. 2F-2G) . These results suggest that ASGR1 271 may be a novel SARS-CoV-2 receptor.

Previous studies have shown that ASGR1 is mainly expressed in liver and 275 peripheral blood mononuclear cells [31] [32] [33] . Using the previously constructed 276 SARS-CoV-2 pseudovirus system, we found that the pseudovirus could infect Huh-7 277 and HepG2 cells (Fig. 1F-1G) .Therefore, we repeated the verification in Huh-7 and Although results obtained by single-cell sequencing showed that ACE2 expression in 282 human liver cells is low, there are reports that ACE2 can be stably expressed in 283 commonly used in vitro liver cell lines. Therefore, we analyzed the expression of 284 ACE2 and ASGR1 mRNAs and the corresponding proteins in Huh-7 and HepG2 cells 285 by qPCR and western blotting, respectively ( Fig. 3D-3E) . The results showed that 286 both Huh-7 and HepG2 cells expressed ACE2 and ASGR1, but the expression level 287 of ASGR1 was significantly higher than that of ACE2. To further test whether the 288 SARS-CoV-2 pseudovirus entered Huh-7 cells through ASGR1 or ACE2, we used 289 CRISPR/Cas9 technology to knock out ASGR1, ACE2, or both. Next, we used 290 SARS-CoV-2 pseudovirus to infect both cell lines. We found that in Huh-7 cells, 291 neither knocking out ACE2 nor ASGR1 alone prevented the SARS-CoV-2 292 pseudovirus from infecting the cells, but when ASGR1 and ACE2 were knocked out 293 simultaneously, it was evident that the efficiency of SARS-CoV-2 in infecting the cells 294 was significantly reduced, which was confirmed by fluorescence microscopy, flow 295 cytometry, and luciferase assays (Fig. 3F-H) . This suggests that in Huh-7 cells, there 296 may be two independent receptors mediating SARS-CoV-2 infections. and Huh-7, is relatively high, the latter cannot fully reflect the condition of liver cells in 303 the human body. Therefore, we considered further exploration of the immortalized 304 liver cell line THLE-2 and primary liver parenchymal cells. We first determined the 305 expression levels of ACE2 and ASGR1 proteins in THLE-2 and primary liver 306 parenchymal cells; unlike Huh-7 and HepG-2 liver tumor cell lines, THLE-2 and 307 primary liver parenchymal cells expressed nearly no ACE2, whereas ASGR1 was 308 highly expressed ( Fig. 4A-4B ). This suggested that these two cell types may be a 309 suitable cell system for the study of SARS-CoV-2 receptors in liver tissue. We first 310 used SARS-CoV-2 pseudovirus to infect THLE-2 and primary liver parenchymal cells, 311 and found that SARS-CoV-2 could infect both cell types (Fig. 4C-E) .

Given the short culture cycle of primary cells, it is not suitable to screen knockout 313 cells through CRISPR-Cas9-dependent knockout. In THLE-2 and primary liver 314 parenchymal cells, we chose to use galactose, which has been shown to interact with 315 ASGR1 receptors, as well as ASGR1 monoclonal antibody to block ASGR1 binding, 316 to determine whether SARS-CoV-2 pseudovirus infection could be prevented. Using 317 this method, we found that in galactose-treated cells, the proportion of 318 SARS-CoV-2-infected THLE-2 and primary liver parenchymal cells was only slightly 319 decreased with increasing galactose concentrations, which may have been due to the 320 combination of galactose and ASGR1; later, it was endocytosed into the cells and 321 could not completely hinder the interaction between SARS-CoV-2 and ASGR1 ( Fig.   322 4F-4G). At the same time, when ASGR1 monoclonal antibody was used to treat the 323 cells, we found that the infection rate with SARS-CoV-2 was significantly decreased, 324 which depended on the ASGR1 monoclonal antibody concentration used, but was 325 independent of the incubation time ( Fig. 4H-4I) . These results indicate that ASGR1 is 326 the main receptor for SARS-CoV-2 pseudovirus infection in immortalized and primary 327 liver parenchymal cells, and that ASGR1 monoclonal antibody holds the potential to 328 prevent SARS-CoV-2 infections. After confirming that ASGR1 is a potential new receptor for SARS-CoV-2, we 333 tested whether it could be used for the prevention of SARS-CoV-2 infections. We first 334 obtained soluble ASGR1 protein using 293T cells by transfection with an expression 335 plasmid, followed by immunoprecipitation-based purification (data not shown). After 336 that, we co-incubated with soluble ASGR1 protein and SARS-CoV-2 pseudovirus and 337 then infected THLE-2 and primary liver parenchymal cells. As the concentration of 338 soluble ASGR1 protein and time of co-incubation were increased, the efficiency of 339 SARS-CoV-2 pseudovirus infection gradually decreased (Fig. 5A-5B ). In addition to 340 liver cells, which may depend on ASGR1 for SARS-CoV-2 entry, we wanted to further 341 explore whether soluble ASGR1 could prevent susceptible cells featuring 342 ACE2-mediated entry from being infected by SARS-CoV-2 pseudovirus. We repeated 343 the experiment with H1299, 293T-ACE2, and Huh-7 cells, upon which we found that 344 infection efficiencies in H1299 and Huh-7 cells were significantly decreased, while the 345 decrease was not significant in the case of 293T-ACE2 cells (Fig. 5C-5D) . The 346 expression level of ACE2 in 293T-ACE2 cells was assumed to be much higher than 347 under physiological conditions, thus potentially obscuring the treatment effects. 

In this study, we conducted a gain-of-function screening experiment for the entry 382 of SARS-CoV-2 into host cells, by which we uncovered ASGR1 as a new receptor, 383 which was proven to be the main receptor for SARS-CoV-2 entry into liver cells.

Previous studies confirmed that ASGR1 can promote HBV to infect human liver cells 385 [40]. Moreover, due to its high expression in liver cells, ASGR1 is one of the current 386 candidate targets for the treatment of liver cancer [41, 42] . Conclusive evidence has 387 been obtained by analyzing patient-derived liver samples from COVID-19 autopsies 388

[7]. Compared with ACE2, ASGR1, which is highly expressed in liver cells, is more 389 likely to be the main receptor for SARS-CoV-2 entry. In addition, we found that 390 blocking ASGR1 with antibodies could significantly reduce SARS-CoV-2 infection. In 391 addition, soluble ASGR1 protein could not only inhibit SARS-CoV-2 from infecting 392 liver cells, but also prevented SARS-CoV-2 from infecting cells expressing ACE2 393 receptors, such as H1299 and 293T-ACE2 cells. We also found that soluble ASGR1 394 protein had no significant effect on the proliferation and viability of lung cells, 395 suggesting that ASGR1 protein may be a potential candidate for the treatment of 396 SARS-CoV-2.

In the present study, we could confirm that ASGR1 is the main receptor for 398 SARS-CoV-2 entry into liver cells using various cell lines and primary cells. However, 399 currently, we lack P3 laboratory conditions, and thus lack evidence of a correlation (1) 

Medical Treatment Expert Group for Covid-19

Coronavirus Disease 2019 in China

A pneumonia outbreak associated with a new coronavirus 421 of probable bat origin

A Novel Coronavirus from 425 Patients with Pneumonia in China

A novel 431 coronavirus associated with severe acute respiratory syndrome

SARS-CoV-2 Viral Load in Upper 438 Respiratory Specimens of Infected Patients

Wunderink RG; NU 446 SCRIPT Study Investigators. Circuits between infected macrophages and T cells 447 in SARS-CoV-2 pneumonia

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in 451 patients with COVID-19

SARS-CoV-2 456 productively infects human gut enterocytes

Neuropilin-1 facilitates 463

SARS-CoV-2 cell entry and infectivity

AXL is a 466 candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and 467 bronchial epithelial cells

Isolation and characterization of a bat SARS-like 471 coronavirus that uses the ACE2 receptor

A pneumonia outbreak associated with a new coronavirus 476 of probable bat origin

Gene expression and in 481 situ protein profiling of candidate SARS-CoV-2 receptors in human airway 482 epithelial cells and lung tissue

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial 486 transient secretory cells

SARS-CoV-2 entry factors are highly 490 expressed in nasal epithelial cells together with innate immune genes

Direct or Collateral Liver Damage in 496 SARS-CoV-2-Infected Patients. Semin Liver Dis

Expression of asialoglycoprotein receptor 1 559 in human hepatocellular carcinoma

Activation of the SARS coronavirus spike 562 protein via sequential proteolytic cleavage at two distinct sites

Neuropilin-1 is a host factor for SARS-CoV-2 568 infection

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Interaction network of SARS-CoV-2 with host receptome through spike protein

KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and 582 Kidney. medRxiv

Transferrin receptor is 585 another receptor for SARS-CoV-2 entry

Expression pattern of 587 asialoglycoprotein receptor in human testis

Development of T cells carrying two complementary chimeric antigen receptors

293T-ACE2 cells for 12 hours, replacing the fresh culture and 72 hours later, the 627 expression levels of GFP (F) and luciferase (G) were detected by cell flow cytometer 628 and microplate. Each data represented the mean ± SD of three independent 629 experiments (n=3)

Figure 2. A pooled, genome-wide CRISPR screening for candidate receptor 633 involved in SARS-CoV-2 entry. (A) The outline of genome-wide activation CRISPR 634 screen strategy. The HeLa cells were infected with lentiviral containing 635

Fourteen days post screening with blascicidin, genomic 638 DNA was extracted from monoclonal cells after puromycin selected. The candidate 639 genes were identified by the Sanger sequencing. (B) Validation of MS2-p65-HSF1 in 640 uninfected, infected and HeLa cells with PCR after infection. (C) After infected with 641 the HeLa cells expressing MS2-p65-HSF1 with SAM library, western blot of cell lysate 642 with anti-Cas9 antibody. (D) Statistical analysis of candidate sgRNA. The sgRNA 643 regions of all monoclonal cells were subjected to Sanger sequencing

ASGR1 facilitates SARS-CoV-2 virus pseudotype infection as potently as ACE2

647 CXCR2 or empty, then infected with the GFP-labeled and luciferase SARS-CoV-2 648 virus pesudotype, and visualized by microcopy (E), the expression levels of GFP by 649 cell flow cytometer (F), luciferase were detected by microplate (G) at 72 h post 650 infection. Each data represented the mean ± SD of three independent experiments 651 (n=3) and were analyzed with

the 657 expression levels of GFP by cell flow cytometer (B), luciferase were detected by 658 microplate (C) at 72 h post infection. (D, E) ACE2 and ASSGR1 expression were 659 measured by qPCR (D) and western blot (E) in HEK293T, Huh-7 and HepG2 cells. (F) 660 ACE2 and ASSGR1 expression were measured by western blot in Huh-7 which 661 knock out ASGR1, ACE2, or both. (G-I) SARS-CoV-2 pseudovirus can infect Huh-7 662 cells through ACE2 or ASGR1. Huh-7 cells, which knock out ASGR1, ACE2, or both, 663 were infected with the GFP-labeled and luciferase SARS-CoV-2 virus pesudotype, 664 and visualized by microcopy (G), the expression levels of GFP by cell flow cytometer 665 (H), luciferase were detected by microplate (I) at 72 h post infection

SARS-CoV-2 infects immortalized liver cell lines and primary 671 hepatocytes through ASGR1. (A,B) ACE2 and ASGR1 expression were measured 672 by qPCR (A) and western blot (B) in THLE-2 and primary hepatocytes cells

SARS-CoV-2 pseudovirus can infect THLE-2 and primary hepatocytes cells. THLE-2 674 and primary hepatocytes cells were infected with the GFP-labeled and luciferase 675

luciferase were detected by microplate (E) at 677 72 h post infection. (F,G) Galactose cannot completely prevent the SARS-CoV-2 678 pseudovirus from infecting liver cells. The THLE-2 and primary hepatocytes cells were 679 treated with 50 mM galactose for 0 h

pesudotype, and the infection efficiency was detected by luciferase. (H, I) ASGR1 682 monoclonal antibody can prevent SARS-CoV-2 pseudovirus from infecting liver cells

The THLE-2 and primary hepatocytes cells were treated with 500 ng/L anti-ASGR1 684 antibody for 0 h

then infected with SARS-CoV-2 virus pesudotype, and the infection 686 efficiency was detected by luciferase. Each data represented the mean ± SD of three 687 independent experiments (n=3) and were analyzed with T-test

Soluble ASGR1 protein can prevent SARS-COV-2 pseudovirus from 691 infecting a variety of cells. (A, B) soluble ASGR1 protein could prevent the 692

The THLE-2 and primary 693 hepatocytes cells were infected with SARS-CoV-2 virus pesudotype which incubated 694 with 500 ug/mL soluble ASGR1 for 0 h

) or with 0 ug/mL, 5 700 ug/mL, 50 ug/mL, 500 ug/mL, 5000 ug/mL for 6h (D), then infected with SARS-CoV-2 701 virus pesudotype, and the infection efficiency was detected by luciferase. Each data 702 represented the mean ± SD of three independent experiments (n=3) and were 703 analyzed with T-test

A) Cell proliferation of BEAS-2B cells incubated 708 with 0 ug/mL, 5 ug/mL, 50 ug/mL, 500 ug/mL, 5000 ug/mL soluble ASGR1 protein for 709 24 h. cells was analyzed by CCK8. (B) Apoptosis of BEAS-2B cells incubated or not 710 incubated with 500 ug/mL soluble ASGR1 protein for 24 h were measured by TUNEL 711 staining followed by flow cytometry. Each data represented the mean ± SD of three